<DOC>
	<DOCNO>NCT01139138</DOCNO>
	<brief_summary>This study ass safety panitumumab , irinotecan everolimus give combination treat advance colorectal cancer</brief_summary>
	<brief_title>Safety Study Combination Panitumumab , Irinotecan Everolimus Treatment Advanced Colorectal Cancer</brief_title>
	<detailed_description>This open label uncontrolled phase IB/II study determine maximum tolerate dose ( MTD ) ass efficacy everolimus , irinotecan panitumumab give combination patient metastatic colorectal cancer KRAS wild-type ( WT ) . Patients metastatic colorectal cancer ( mCRC ) fail fluorouracil base first line therapy include . It anticipate approximately 50 patient enrolled period 24 month</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age &gt; 18 year Histological diagnosis colorectal cancer KRAS wild type Metastatic disease amenable resection Measurable disease assess CT scan use RECIST criterion Received fail fluoropyrimidine therapy Radiographically document disease progression per RECIST criterion For phase 1b group , ECOG PS 01 For phase 2 group , ECOG PS 02 Adequate bone marrow function haemoglobin &gt; 100 g/L , platelet &gt; 100 X 109/l ; neutrophil &gt; 1.5 X 109/l within 7 day enrolment Adequate renal function , calculate creatinine clearance &gt; 40 ml/min ( Cockcroft Gault ) within 7 day enrolment Adequate hepatic function serum total bilirubin &lt; 1.25 X upper limit normal range ALT AST &lt; 2.5xULN ( &lt; 5xULN liver metastasis present ) within 7 day enrolment Magnesium ≥ low limit normal within 7 day enrolment . Fasting serum cholesterol ≤ 7.75mmol/L AND fast triglyceride ≤ 2.5 x ULN . Note : In case one threshold exceed , patient include initiation appropriate lipid lower medication . Life expectancy least 12 week Negative pregnancy test ≤ 72 hour commence study treatment ( woman childbearing potential ) . Written inform consent include consent biomarker study Presence KRAS mutation tumour sample For Phase 1b group , patient prior pelvic radiotherapy . Systemic chemotherapy , immunotherapy , approve proteins/antibodies investigational agent within 4 week prior commence study treatment Radiotherapy within 14 day commence study treatment . Unresolved toxicity prior systemic therapy radiotherapy Medical psychiatric condition compromise patient 's ability give inform consent complete protocol Prior treatment drug target EGFR cetuximab , panitumumab erlotinib Prior therapy mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) Prior therapy irinotecan CYP3A4 enzyme induce anticonvulsant medication ≤ 14 day prior study treatment . Ketoconazole ≤ 7 day study treatment . Uncontrolled diabetes mellitus define fast glucose &gt; 1.5 x ULN . Known cirrhosis , chronic active hepatitis , chronic persistent hepatitis Patients know interstitial lung disease severely impaired lung function Patients active bleeding diatheses . Any uncontrolled clinically significant cardiac disease , arrhythmias angina pectoris Active inflammatory bowel disease bowel disease cause chronic diarrhoea Chronic treatment immunosuppressives Patients know history HIV seropositivity Patients severe and/or uncontrolled medical condition infection Untreated symptomatic CNS metastases Patients history another primary malignant disease Pregnancy lactation . Women partner woman childbearing potential use effective contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Colorectal Carcinoma</keyword>
	<keyword>Colorectal Tumors</keyword>
	<keyword>Neoplasms , Colorectal</keyword>
</DOC>